< Back to companies
Berry Genomics (贝瑞和康)

Berry Genomics (贝瑞和康)

Beijing, China

Berry Genomics (贝瑞和康) is a leading company in clinical genomics and life science in China. Berry Genomics is dedicated to research, development and commercialization of genetic test technologies in clinical applications. Berry Genomics aims to assist accurate diagnosis of diseases throughout the full human life circle, and to improve human health. As a company with strong R&D capability, Berry Genomics pioneered the first NGS-based genetic test, NIPT, in China back in 2010. The company currently provides NGS- based tests for many genetic diseases and cancers from preconception to adulthood. Berry Genomics is leading in the clinical study of early clinical detection of liver cancer in the world. Exploring the use of the third-generation sequencing technology in both clinical field and scientific study is ongoing.

Only accessible to MedStartr community members. Join now

Company Info

Founded
2010
Website
berrygenomics.com/

Categories

BiotechPrecision Medicine/Diagnostics
Only accessible to MedStartr community members. Join now

What do you think of Berry Genomics (贝瑞和康)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Innovation

Clinical Benefit

Feasibility

Scalability

Only accessible to MedStartr community members. Join now